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Chae Gyu Park,3,4 and Ralph M. Steinman3,4
The targeted delivery of Ags to dendritic cell (DCs) in vivo
greatly improves the efficiency of Ag presentation to T cells
and allows an analysis of receptor function. To evaluate
the function of Langerin/CD207, a receptor expressed by
subsets of DCs that frequently coexpress the DEC205/
CD205 receptor, we genetically introduced OVA into the
C terminus of anti-receptor Ab H chains. Taking advan-
tage of the new L31 mAb to the extracellular domain of
mouse Langerin, we find that the hybrid Ab targets ap-
propriate DC subsets in draining lymph nodes and spleen.
OVA is then presented efficiently to CD8 and CD4 T
cells in vivo, which undergo 4–8 cycles of division in 3 days.
Peptide MHC I and II complexes persist for days. Dose re-
sponse studies indicate only modest differences between Lan-
gerin and DEC receptors in these functions. Thus, Langerin
effectively mediates Ag presentation. The Journal of Immu-
nology, 2008, 180: 3647–3650.
D endritic cells (DCs)5 are specialized APCs able to con-trol T cell immunity in vivo (1). Several DC subpopu-lations are known (2). These typically express distinct
receptors for Ag uptake and capacities for Ag processing (3).
Many differentially expressed receptors include molecules with
C-type lectin domains (4) such as DEC205/CD205 on CD8
DCs, dermal DCs, and Langerhans cells (LCs) and 33D1/
DCIR2 on CD8 cells (2, 3, 5, 6).
Langerin/CD207 is a type II transmembrane protein (5). Orig-
inally, Langerin was thought to be LC-specific, but it is expressed
onotherDCs, especiallyCD8DECDCs in spleen (7) and skin
draining lymph nodes (pLN), although at lower levels (6, 8, 9).
The expressionofLangerinbyCD8DECDCs is primarily seen
in BALB/c mice but is much reduced in C57BL/6 mice (8). Lan-
gerin recognizes mannose, n-acetylglucosamine, fucose, and sulfated
sugars (7,10,11).LangerinalsobindspathogenssuchasHIV(12)and
Candida albicans (13). Langerin is responsible forBirbeck granule for-
mation within LCs (5). Both Birbeck granules and Langerin are in-
volved in endocytosis (5, 14). In human epidermal LCs, Langerin is
predominantly found in an endosomal recycling compartment (14).
Inmurine epidermis, Langerinwas found to colocalizewithMHC
II in situ (15). Abs to Langerin can be internalized (5), but it is not
known whether this mediates Ag presentation to T cells.
A new way to assess receptor function, including in vivo, is to
deliver Ags within anti-receptor mAbs, which selectively bind
to the receptor and initiate Ag uptake, processing, and presen-
tation on MHC products. Depending on the maturation state
of the targeted DCs, receptor-mediated targeting enhances or
inhibits T cell responses (3, 16–18). The role of DC subsets
expressing select receptors, as well as the role of the receptors
themselves in Ag presentation, might therefore be determined
by using specific mAbs as Ag carriers.
In this study, we use a newly developed mAb to the extracel-
lular domain of mouse Langerin to begin to study the conse-
quences of Ag uptake via Langerin in vivo (8). We have cloned
the H and L chains of this mAb and engineered the H chain to
encode OVA. We will show that OVA targeting to Langerin
results in efficient presentation to OVA-specific CD4 and
CD8 transgenic T cells.
Materials and Methods
Mice
C57BL/6J and BALB/cJ mice were purchased from Charles River or Jackson Lab-
oratories and used at 6–8 wk of age. OVA-specific, TCR transgenic, OT-I (C57BL/
6-Tg(TcraTcrb)1100Mjb/J) andOT-II (C57BL/6-Tg(TcraTcrb)425Cbn/J)mice
were used as described (17). All animals were maintained under specific pathogen-
free conditions and used under institutional guidelines.
Reagents
Anti-CD16/32, FITC-anti-CD11c, allophycocyanin-anti-CD8, anti-CD4,
and PE-V2 were from BD Biosciences or eBioscience. Other reagents were
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RPMI 1640 and DMEM (Invitrogen Life Technologies/GIBCO), ACK (am-
monium chloride potassium) lysing buffer (BioSource International), 30%
BSA Solution (Sigma-Aldrich), Alexa Fluor 647 labeling kit (Invitrogen Life
Technologies/Molecular Probes), and EZ-Link Biotin (Pierce).
Cloning, engineering and production of anti-Langerin Ab
Cloning of V regions from rat mAbs and engineering of hybrid mAbs with
mouse IgG1 H and  light constant regions was described for mAbs III/10
(control Ig), NLDC145 (anti-DEC205) (16), and 33D1 (anti-DCIR2) (3).
Similarly, the V regions of anti-mouse Langerin mAb (8) were cloned from
RNAs of the L31 hybridoma with the 5 RACE system (Invitrogen Life Tech-
nologies) using rat IgG2a-specific oligonucleotides (5-CATCCCAGGGTCA
CCATGGA-3 and 5-CTGTTGTTTCAGCTGAGGAGACTG-3) and rat
-specific oligonucleotides (5-CAACCTCACAGGTATAGAG-3 and 5-G
AAGATGGATACAGTTGGTGCAGCATC-3) following the manufactur-
er’s instructions. An OLLAS epitope sequence was inserted as a linker between
the H chain and OVA for the detection of hybrid mAbs by an anti-OLLAS tag
mAb (19). Hybrid mAbs were produced (3) and receptor binding was verified
using Chinese hamster ovary (CHO) transfected cells by FACS.
Adoptive transfer and T cell proliferation responses
OVA-specific transgenic CD8 or CD4 T cells were prepared from lymph
node and spleen cell suspensions of OT-I or OT-II mice (17). T cell prolifer-
ation was evaluated by injecting individual mice with either 2–3 106OT-I or
3–5  106 OT-II cells, labeled at 107 cells/ml with 5 M CFSE (Invitrogen/
Molecular Probes) for 10 min at 37°C. Targeting mAbs were injected s.c. 24 h
later. CFSE dilution was evaluated 3 days later by FACS after surface staining
for CD4 (OT-II) or CD8 (OT-I) and V2 (OVA-specific TCR). To address
Ag persistence, mAbs were injected 14, 3, or 1 day before T cell transfer.
Evaluation of Ag targeting in vivo
To evaluate mAb targeting to DCs by FACS, animals were injected s.c. with 10
g of L31-OLLAS-OVA. Spleen and pLN (popliteal, cervical, inguinal, axil-
lary, and brachial) were harvested 24 h later. DCs were enriched by low density
on dense BSA (8), and the cells were stained with anti-CD11c-FITC and anti-
OLLAS-Alexa Fluor 647. For immunofluorescence, mice were injected s.c.
with 25 g of L31-OLLAS-OVA or control Ig. Twelve hours later, tissue sec-
tions were analyzed with a Zeiss LSM 510 system (8).
Statistical analysis
The Student t test was applied to reveal significant differences in fold clonal
expansion of transgenic T cells, defined as the ratio of the number of cells with
more than one division to the number of transgenic T cells in control mice that
had not received Ag. Our results are expressed as the mean SE. In the figures,
p values of0.05 are labeled with a single asterisk () in contrast to p values of
0.01 () or 0.001 ().
Results and Discussion
Preparation of anti-Langerin-OLLAS-OVA hybrid mAb
To examine the capacity of the Langerin receptor to process and
present proteins through the MHC I and II pathways, we ge-
netically engineered mAbs against Langerin (8), DEC (16),
DCIR2 (3), and a nonreactive control Ig (ISO) to expressOVA.
To track Ab expression and binding, we added a linker tag se-
quence between the C terminus of the Ab H chain and OVA
named OLLAS, recognized by an anti-OLLAS mAb (19) (Fig.
1A). In each case, the fusion H chain had a molecular mass of
110 kDa (Fig. 1B) and reacted with anti-mouse Ig, anti-
OVA, and anti-OLLAS mAbs by Western blotting (Fig. 1C).
By FACS, each fusion mAb bound appropriately to CHO
transfectants expressing receptor (Fig. 1D, gray histograms),
but not to untransfected CHO (CHO/Neo; Fig. 1D, black his-
tograms), while the control Ig-OVA did not bind to Langerin,
DEC, or DCIR2 (Fig. 1D). Thus, each mAb to three endocytic
receptors can be engineered to express both OVA as an Ag and
OLLAS as a sensitive tag.
Anti-Langerin targets selectively and systemically to DCs in vivo
To assess targeting of anti-Langerin to DCs in vivo, we injected
BALB/c mice s.c. in the footpads with anti-Langerin-OLLAS-
OVA or control mAb and detected OLLAS by FACS analysis
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FIGURE 1. Genetic engineering of
OVA into the anti-Langerin mAb H
chain. A, Diagram of engineered mAbs
fused toOVA, withOLLAS tag between
H chain and OVA. mC, mouse C;
mIgG1, mouse IgG1. B, Coomassie-
stained 10% SDS-PAGE reducing gel
comparing chimeric anti-Langerin
(Lang), anti-DEC, anti-DCIR2, and
control Ig -OLLAS-OVA, with molecu-
lar mass in kDa. C, Western blots of hy-
brid mAbs using HRP-conjugated anti-
mouse IgG1 (left), anti-OVA (middle),
or anti-OLLAS biotin followed by
HRP-conjugated streptavidin (right).D,
Binding of mAbs to CHO/mouse
Langerin (mLang), CHO/mouse
DEC (mDEC), CHO/mouse DCIR2
(mDCIR2) (gray), and control CHO/
Neo cells (black), using graded doses
(0.02–2 g) of recombinant mAbs
and anti-OLLAS-Alexa Fluor 647
(OLLAS). ISO stands for isotype
control.
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and immunofluorescence. The isotype control mAb (ISO-
OLLAS-OVA, where ISO is isotype control) did not bind to
DCs (Fig. 2A, top), whereas anti-Langerin-OLLAS-OVA tar-
geted all subsets of Langerin cells, e.g., both CD11chigh
(25 5% of Langerin cells) and CD11clow (70 5% of
Langerin cells) DCs in spleen and in pLN (Fig. 2A). By FACS,
theDC labeling by anti-OLLAS tagmAbwas selective for those
CD11c cells that also were labeled with anti-Langerin (data
not shown). By immunofluorescence of tissue sections, anti-
OLLAS also selectively stained cells reactive with anti-Langerin
in the T cell area of pLN (Fig. 2B). These results indicate that
s.c. injection of hybrid anti-Langerin Abs targets Langerin
DCs selectively and systemically (spleen) in vivo.
Targeting proteins to DCs and LCs in vivo via anti-Langerin
C57BL/6 mice were injected with graded doses of each
OLLAS-OVA fusion mAb 1 day after inoculating CFSE-la-
beled OT-I or OT-II T cells, the latter to monitor Ag presen-
tation in vivo. After 3 days, pLN and spleen were evaluated for
T cell proliferation by CFSE dilution and the total number
of expanded CFSE-low cells. Anti-DEC, anti-Langerin, and
anti-DCIR2- OLLAS-OVA induced responses by MHC I-
restricted CD8 OT-I cells, as well as MHC II-restricted
OT-II cells, in both spleen and pLN. Virtually all T cells
entered cell cycle and underwent 4–8 cell divisions after a
single dose of 3 g of anti-Langerin-OLLAS-OVA (Fig. 3A).
A                                      B Langerin Anti-OLLAS
AVO-SALLO-niregnaL
AVO-SALLO-OSI
MeshSpleen pLN
Isotype
control
24 hrs
Anti-OLLAS
c11DC
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FIGURE 2. Detection of recombinant mAbs after targeting Langerin in vivo. A, BALB/c mice were injected s.c. with 10 g of anti-Langerin or control Ig
-OLLAS-OVA. Twenty-four hours later, DCs were enriched and analyzed by FACS using anti-OLLAS-Alexa Fluor 647 mAb. The selectively targeted CD11chigh
and CD11clow DCs are indicated by an arrowhead and arrow, respectively, where the latter are the tissue-derived Langerin cells. B, Twelve hours postinoculation
with 25 g of anti-Langerin-OLLAS-OVA to BALB/c mice, lymph node sections were stained with anti-OLLAS biotin and streptavidin-Alexa Fluor 555 (red),
anti-Langerin Alexa Fluor 647 (green), and anti-B220-FITC followed by anti-FITC Alexa Fluor 488 (blue). ISO stands for isotype control.
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FIGURE 3. Anti-Langerin-OVA in-
duces strong in vivo proliferation of
CD8 and CD4 transgenic T cells. A,
C57BL/6 mice were injected i.v. with
2–5  106 CFSE-labeled OT-I or
OT-II T cells and, 24 h later, with
graded doses of the indicated OLLAS-
OVA fusion mAb s.c. Three days after
the hybrid mAb injection, pLN and
spleen were harvested and expansion of
CD8 or CD4V2 cells was evaluated
by FACS for CFSE dilution. Panels are
typical of 2–4 experiments. B, Bar
graphs to quantify T cells undergoing
more than one division (fold clonal ex-
pansion; see Materials and Methods) on
day3after the inoculationof3gof anti-
Langerin, anti-DEC, or anti-DCIR2
-OLLAS-OVA. Means and SE values
are shown for six experiments. The
Greek letter alpha () stands for “anti,”
and ISO stands for isotype control.
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Similar results were obtained when we inoculated fusion mAbs
lacking the OLLAS tag, indicating that the OLLAS sequence
did not affect Ag presentation in vivo (data not shown).We also
reproduced prior work (3) showing that 33D1 anti-DCIR2,
which selectively targets CD8 DCs, was more efficient in in-
ducing CD4 T cell expansion while anti-DEC was more effi-
cient for CD8 T cells (Fig. 3B). Anti-Langerin-OVA was in-
termediate in its behavior, slightly less effective than anti-DEC
for triggering OT-I expansion but more effective for OT-II T
cells (Fig. 3B). The observations with OT-II cells in C57BL/6
mice were confirmed on DO11.10 T cells in BALB/c mice
(data not shown). Taken together, Langerin delivers OVA Ag
for efficient presentation on MHC I and II products.
Long-lasting presentation of OVA delivered via anti-Langerin
To evaluate the persistence of presented Ag, we injected the dif-
ferent OVA fusion mAbs and 1, 3, or 14 days later we injected
CFSE-labeled, OVA-specific OT-I or OT-II cells. Presentation
to CD8 T cells after one dose of anti-Langerin-OLLAS-OVA
was long-lasting (Fig. 4), being vigorous in pLN and spleen 14
days after mAb injection. In contrast, as shown previously (3)
presentation by CD8 DCs via anti-DCIR2 persisted for 3
days (Fig. 4). Functional peptide MHC complexes persisted to
a slightly greater extent at day 14 when OVA was targeted via
Langerin rather than DEC (Fig. 4).
Prior observations had shown that Langerin acts as an endo-
cytic receptor in vitro with cultured human LCs. In this study
we show that Langerin mediates Ag presentation in vivo by tar-
geting the receptor selectively within the new L31 mAb to the
Langerin extracellular domain (8). Langerin delivers Ag to both
CD4 and CD8T cells, and the presentation is prolonged for
several days. When anti-Langerin-OVA is compared with anti-
DEC-OVA where DEC and Langerin expression is to a large
extent confined to the same subsets of DCs, e.g., CD8 DCs
and LCs, anti-Langerin is slightly less efficient than anti-DEC
for presentation onMHC I andmore efficient forMHC II, and
Langerin-based presentation also seems to persist slightly
longer. In contrast, when anti-Langerin-OVA is compared with
anti-DCIR2-OVA, presentation of anti-Langerin is less efficient
forMHCII butmore efficient toMHCI. Although theOT-I and
OT-II transgenic T cells have been valuable in this study for car-
rying out quantitative comparisons of the efficacy of different en-
docytic receptors, the functional consequences of Ag presentation
are best conducted with other more clinically relevant Ags and the
infrequent T cells in the polyclonal repertoire.
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